Scientific Reports (Dec 2022)

A novel small molecule inhibitor of human Drp1

  • Ayeshah A. Rosdah,
  • Belinda M. Abbott,
  • Christopher G. Langendorf,
  • Yali Deng,
  • Jia Q. Truong,
  • Helen M. M. Waddell,
  • Naomi X. Y. Ling,
  • William J. Smiles,
  • Lea M. D. Delbridge,
  • Guei-Sheung Liu,
  • Jonathan S. Oakhill,
  • Shiang Y. Lim,
  • Jessica K. Holien

DOI
https://doi.org/10.1038/s41598-022-25464-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Mitochondrial dynamin-related protein 1 (Drp1) is a large GTPase regulator of mitochondrial dynamics and is known to play an important role in numerous pathophysiological processes. Despite being the most widely used Drp1 inhibitor, the specificity of Mdivi-1 towards human Drp1 has not been definitively proven and there have been numerous issues reported with its use including off-target effects. In our hands Mdivi-1 showed varying binding affinities toward human Drp1, potentially impacted by compound aggregation. Herein, we sought to identify a novel small molecule inhibitor of Drp1. From an initial virtual screening, we identified DRP1i27 as a compound which directly bound to the human isoform 3 of Drp1 via surface plasmon resonance and microscale thermophoresis. Importantly, DRP1i27 was found to have a dose-dependent increase in the cellular networks of fused mitochondria but had no effect in Drp1 knock-out cells. Further analogues of this compound were identified and screened, though none displayed greater affinity to human Drp1 isoform 3 than DRP1i27. To date, this is the first small molecule inhibitor shown to directly bind to human Drp1.